Skip to Content


Dosage Form: intravenous solution

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.


Pentagastrin Description

Pentagastrin, a diagnostic aid, is supplied as a sterile solution (1.1 ml/5 ml vial) containing:

  • 250 micrograms Pentagastrin per ml
  • 0.8 mg Methylparaben and 0.2 mg Propylparaben per mL
  • 0.9 mg sodium chloride per mL
  • pH 8

Pentagastrin - Clinical Pharmacology

The exact mechanism by which Pentagastrin stimulates gastric acid, pepsin, and intrinsic factor secretion is unknown; however, since Pentagastrin is an analogue of natural gastrin, it is believed that it excites the oxyntic cells of the stomach to secrete to their maximum capacity. Pentagastrin stimulates pancreatic secretion, especially when administered in large intramuscular doses. Pentagastrin also increases gastrointestinal motility by a direct effect on the intestinal smooth muscle. However, it delays gastric emptying time probably by stimulation of terminal antral contractions, which enhance retropulsion.

OTHER ACTIONS/EFFECTS Pentagastrin increases blood flow in the gastric mucosa, inhibits absorption of water and electrolytes from the ileum, and promotes sodium and chloride diuresis. It causes contraction of the smooth muscle of the lower esophageal sphincter when administered intravenously. Pentagastrin produces an increase in the motor activity of the colon and rectum

ONSET OF ACTION 10 minutes

TIME TO PEAK EFFECT 20 to 30 minutes

DURATION OF ACTION 60 to 80 minutes

Indications and Usage for Pentagastrin

  1. Anacidity (diagnosis)—Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection.
  2. Hypersecretory conditions, gastric (diagnosis)—Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor

Pentagastrin Dosage and Administration

The intravenous infusion dose has ranged from 0.1 to 12 mcg (0.0001 to 0.012 mg) per kg of body weight per hour administered in a 0.9% sodium chloride injection. It can also be used as a subcutaneous injection for gastric function study with a dose of 6 mcg (0.006 mg) per kg of body weight.


The following may affect Pentagastrin’s  action:

  • Antacids, anticholinergics, histamine H2-receptor antagosnists, or omeprazole
  • Acute, obstructing, penetrating or bleeding peptic ulcers

Storage and Handling

Keep refrigerated between 2 and 8C. Protect from light


Figure 1

Pentagastrin solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:51808-207
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Pentagastrin (Pentagastrin) Pentagastrin 250 ug  in 1.6 mL
Inactive Ingredients
Ingredient Name Strength
METHYLPARABEN 1.8 mg  in 1.6 mL
PROPYLPARABEN 0.2 mg  in 1.6 mL
# Item Code Package Description
1 NDC:51808-207-01 5 mL in 1 VIAL
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
Unapproved drug other 06/19/2012
Labeler - AnazaoHealth Corporation (011038762)
Name Address ID/FEI Operations
AnazaoHealth Corporation 011038762 MANUFACTURE
Revised: 06/2012
AnazaoHealth Corporation